5.20 0.00 (0.00%)
After hours: 4:00PM EST
|Bid||4.15 x 100|
|Ask||15.00 x 100|
|Day's Range||5.10 - 5.55|
|52 Week Range||4.80 - 11.15|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Minerva Neurosciences (NERV) initiates a phase III study to evaluate MIN-101 as monotherapy to treat negative symptoms in schizophrenia patients.
Minerva Neurosciences Inc (NASDAQ:NERV), a pharmaceuticals, biotechnology and life sciences company based in United States, Check out our latest analysis for Minerva Neurosciences What’s the opportunity in NERV? Great newsRead More...
The EU approves of Minerva's (NERV) amendment of MIN-202 license agreement with Janssen. Per the deal, Minerva will receive an upfront payment from Janssen.
The Emeryville, Calif.-based firm secures FDA approval for Gocovri as a treatment for dyskinesia in Parkinson's disease patients.
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 27 cents. Minerva Neurosciences shares have fallen 43 percent since the beginning of the year. The stock has dropped ...
Minerva Neurosciences, Inc. (NERV) announced that it is on track to begin phase III studies on its key schizophrenia pipeline candidate MIN-101 in the second half of this year, as planned.
Minerva Neurosciences and Johnson & Johnson have amended their co-development agreement for the experimental insomnia drug MIN-202.
Minerva Neurosciences, Inc. (NERV) announced plans for its phase III and phase IV clinical development of pipeline candidate MIN-101.
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 30 cents. Minerva Neurosciences shares have fallen 43 percent since the beginning of the year. The stock has climbed ...
The Waltham, Massachusetts-based company said it had a loss of 27 cents per share. For the year, the company reported a loss of $31 million, or 99 cents per share. Minerva Neurosciences shares have decreased ...